Geoff Oxnard MD @geoff_oxnard Twitter profile

Pinned Tweet

Geoff Oxnard MD

11 months

1/10 I left #ASCO23 last week feeling INSPIRED about the pace of progress & discovery for cancer patients! I'm excited about2⃣ precision oncology themes from the meeting, and it seems others in the oncology community share my excitement:

4

18

67

Last Seen Profiles

@ichikahikari_

@PCcityPolice

@vlady_tery

@wjx0fwkxGYhOQz0

@SSB_JP_Official

@ohioiaaa

@IamKeishaKeisha

@notmanagement

@apaasi

@0xNxsh

@tekooila

@accesshollywood

@_QUEENTUT_

@papamekdi

@namasayamelki

@jocelynseip

@listszz

@ka024609

@nagajuseyoo

@buchii_gustavo

@VelshiMSNBC

@ella_bosslady

@thornprotector

@_JLMartinez_

@Samuel_Levy_

@Raskolnikow_21

@WickedLipsss

@connecthackney

@jycanvas

@UCCSMBB

@alhadab

@movieswithrid

@DAODenver

@JasCephasJones

@septic_berry

@cannibalxing

Geoff Oxnard MD

@geoff_oxnard

3 years

Oncologists, what's more HOPEFUL than: - caring for a tragically young pt w refractory cancer... - achieving response to investigational tx... - referring him/her back to local doc... - and then stumbling upon him/her years later on TWITTER, now married and thriving?!?

3

8

235

Geoff Oxnard MD

@geoff_oxnard

4 years

1

81

216

Geoff Oxnard MD

@geoff_oxnard

5 years

Here come 4th generation EGFR inhibitors! New allosteric EGFR inhibitor from Pasi Janne, Nathanial Gray & Michael Eck @DanaFarber , synergistic with osimertinib, just out @CD_AACR . @EGFRResisters #LCSM

2

63

165

Geoff Oxnard MD

@geoff_oxnard

1 year

Super exciting to work with @genentech on this creative analysis in @NatureMedicine of IMpower150 demonstrating the power of ctDNA monitoring to predict outcome on chemoIO:

3

44

136

Geoff Oxnard MD

@geoff_oxnard

4 years

More cool work from the Janne lab @DanaFarber figuring out the vulnerabilities of dormant EGFR-mutant NSCLC on TKI. Inhibiting MEK plus YAP/TEAD tips these surviving cells into apoptosis!

3

44

117

Geoff Oxnard MD

@geoff_oxnard

4 years

Nice paper from @MDAndersonNews showing that levels of tumor DNA shed are prognostic. Let's start using liquid biopsies as quantitative tools not just positive/negative! @CCR_AACR

3

48

112

Geoff Oxnard MD

@geoff_oxnard

4 years

For EGFR resistance, remember to biopsy and test for MET amp! SAVANNAH trial of osimertinib / savolitinib now enrolling globally: @LeciaSequist

1

37

85

Geoff Oxnard MD

@geoff_oxnard

2 years

So cool to see EGFR C797S being targeted @AACR ! Proud to support a new paradigm of real-time ctDNA response assessment in first-in-human trials - congrats to @ElaineShumMD & @BlueprintMeds :

0

25

82

Geoff Oxnard MD

@geoff_oxnard

2 years

Two vaccinated! 💉🩹 The younger two will have to wait. Thank you @challiance ! ❤️

1

70

Geoff Oxnard MD

@geoff_oxnard

5 years

Our new editorial @CCR_AACR : "Effective cancer genotyping -- many means to one end" . A joy to write with Dr. Catherine Meador @BrighamWomens , soon a fellow @DanaFarber ! Many tools available so ALL patients can receive effective cancer genotyping.

1

31

63

Geoff Oxnard MD

@geoff_oxnard

5 years

Does testing error underlie liquid biopsy discordance? "Bake-off" from @AstraZeneca suggests that, in the wild world of plasma NGS assays, technical factors impact assay variability more than we realize:

1

35

65

Geoff Oxnard MD

@geoff_oxnard

1 year

Super excited for our #ASCO23 ctDNA evidence! 🧬ctDNA monitoring w @BrunaPellini @genentech & @NIVokes @Regeneron 🧬ctDNA tumor fraction w @ChristianRolfo @flatironhealth & @LungMAP 🧬ctDNA fusions w @pashtoonkasi 🧬ctDNA HRRm w @pfizer See you there!

0

15

66

Geoff Oxnard MD

@geoff_oxnard

5 years

Trust your favorite liquid biopsy assay? Our @DanaFarber @DCcloudy data comparing 2 hybrid capture plasma NGS assays finds what many suspected - targetable fusions are being missed. Fortunately, assays are constantly improving, as they should be!

1

26

58

Geoff Oxnard MD

@geoff_oxnard

3 years

So excited to publish w @FoundationATCG on 'The pan-tumor landscape of targetable kinase fusions in ctDNA' in @CCR_AACR : 571 ctDNA fusions, reliable detection when adequate ctDNA shed, no evidence of dropped fusions apparent w some liquid biopsies!

0

25

60

Geoff Oxnard MD

@geoff_oxnard

4 years

With TKI for METex14 now SOC, even more essential that all NSCLC pts get NGS (tissue, plasma, or both)! Don't choose pts based on clinical features ➡️ NGS for young (ALK, ROS1) & old (BRAF, MET), for adeno (EGFR, etc) & squam/poorly diff (MET):

Geoff Oxnard MD

@geoff_oxnard

5 years

Our new editorial @CCR_AACR : "Effective cancer genotyping -- many means to one end" . A joy to write with Dr. Catherine Meador @BrighamWomens , soon a fellow @DanaFarber ! Many tools available so ALL patients can receive effective cancer genotyping.

1

31

63

2

33

60

Geoff Oxnard MD

@geoff_oxnard

3 years

Headed back to clinic - what a privilege to be caring for lung cancer patients again! Weekly at @The_BMC (appts 617-638-8000) while I continue development of precision diagnostics at @FoundationATCG . Thank you Drs. Matt Kulke and Umit Tapan for your collaboration!

1

0

57

Geoff Oxnard MD

@geoff_oxnard

1 year

So grateful for the FASCO recognition! Has been incredibly rewarding to serve & volunteer these 18 yrs since my first @ASCO . Please volunteer! 🎉 CONGRATS 👏 to all the ASCO awardees! See you all at #ASCO23 🏙️.

6

0

59

Geoff Oxnard MD

@geoff_oxnard

2 years

"Tumor agnostic efficacy of selpercatinib" - now showing at the posters! @VivekSubbiah @alexdrilon

1

14

56

Geoff Oxnard MD

@geoff_oxnard

6 years

Sensitivity of liquid biopsy actually quite GOOD when there is high tumor content (>5%AF). But if you only see low level mutations, you need a biopsy to look for what you might have missed! @DanaFarber #ASCO18

3

28

53

Geoff Oxnard MD

@geoff_oxnard

4 years

We can't let cancer pts be the hidden victims of #COVID19 . We can take care of them, we can do this. via @BostonDotCom @sands_jacob @DanaFarber

The pandemic's hidden victims: sick or dying, but not from coronavirus

“People like my husband now are dying not because of COVID, but because the health care system just cracked open and swallowed them up.”

www.boston.com

2

14

50

Geoff Oxnard MD

@geoff_oxnard

2 years

A joy to contribute to this @DanaFarber work led by the talented Yoshi Kobayashi, incl 2 pts of mine I remember fondly. Fusions are a key targetable component of EGFR resistance! Those days of EGFR T790M seem so long ago @RielyMD ...

Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors

Nature Communications - Fusion genes have been proposed as a potential mechanism of resistance to EGFR tyrosine kinase inhibitors (TKIs) in lung cancer. Here, the authors identify gene fusions that...

www.nature.com

1

11

51

Geoff Oxnard MD

@geoff_oxnard

3 years

Now out in JCOPO @ASCO_pubs with @DrMarkAwad : clinicogenomics of >1500 NSCLC pts w METex14 mutations detected on NGS: Similar prevalence and distribution in tumor tissue DNA (left) vs ctDNA (right):

0

20

51

Geoff Oxnard MD

@geoff_oxnard

4 years

Nice @CCR_AACR report showing MET amp can mediate TKI resistance in ALK positive NSCLC, highlighting the value of NGS at resistance. And pts can get free plasma NGS on our SPACEWALK study! See for details.

1

18

47

Geoff Oxnard MD

@geoff_oxnard

5 years

Excited to be nominated for the Cancer Community (C2) Precision Medicine Award with my friend Barbara Gitlitz! Looking forward to the event tonight in NYC, thanks to ⁦ @sciam ⁩ and ⁦ @AstraZenecaUS ⁩. ⁦ @DanaFarber ⁩ @TheALCF ⁩

3

4

42

Geoff Oxnard MD

@geoff_oxnard

2 years

Bravo @ChristianRolfo presenting our new RWD w @flatironhealth studying the value of early LBx during the "diagnostic odyssey" of NSCLC pts. A compelling paradigm to help pts start precision tx earlier. Prospective validation planned!

1

11

45

Geoff Oxnard MD

@geoff_oxnard

3 years

Nice report in @JTOonline showing that even when starting with tissue NGS, genomic yield can be increased by using liquid NGS as backup. 'Reflex' can go both ways - oncologists needs to be ready to use both tissue and liquid platforms to maximize effective genotyping.

JTO & JTO CRR

@JTOonline

3 years

Li et al. assessed an optimized workflow integrating multiple molecular detection platforms to improve efficiency in pt selection for targeted therapy among pts newly diagnosed w/metastatic #NSCLC w/limited tissue samples #JTOCRR @OncologyAdvance @IASLC

0

15

32

0

8

44

Geoff Oxnard MD

@geoff_oxnard

9 months

🎉 My first paper in JLB @isliquidbiopsy ! 🤓 A pleasure to collaborate with SCRUM-Japan to describe pan-tumor bTMB 🩸concordance w TMB 🔬& identification of cancer pts w better outcomes on IO:

2

16

42

Geoff Oxnard MD

@geoff_oxnard

4 years

Beautiful concept from parents' @exeterucc virtual service yest: "Social distancing" is a misnomer! Actually want PHYSICAL distancing - can we do it while maintaining our SOCIAL connection? Virtual coffeebreaks, storytimes, family dinners, group visits, ETC. We can do this.

2

12

39

Geoff Oxnard MD

@geoff_oxnard

5 years

What a crazy finding - of 74 canine pulmonary adenos, 26 had HER2 V659E TMD mutations which are vanishingly rare in human lung adenocarcinoma! Want to launch a co-clinical trial of afatinib in dogs w HER2 mutant NSCLC? ⁦ @CCR_AACR ⁩

2

12

39

Geoff Oxnard MD

@geoff_oxnard

4 years

I am honored to be featured in the YOUR Cancer #C2Awards podcast for my work in precision cancer care! It was wonderful to speak with Scientific American and discuss the patient-centered future of oncology. @AstraZeneca @Sciam @GO2Foundation

Scientific American

@sciam

4 years

Detecting lung cancer through blood tests. Geoffrey Oxnard winner of the 2019 C2 Catalyst for Precision Medicine Award, tells us about the new technique [Sponsored by @AstraZenecaUS ] #C2Awards

1

38

155

6

3

40

Geoff Oxnard MD

@geoff_oxnard

3 years

Excited to launch, for research use, F1-Tracker: a bespoke ctDNA MRD/monitoring assay built off variants detected on actionable @FoundationATCG tissue CGP, in collaboration with @NateraOncology !

3

13

41

Geoff Oxnard MD

@geoff_oxnard

5 years

FDA Approves Atezolizumab Regimen for Frontline Small Cell Lung Cancer via @onclive

0

18

35

Geoff Oxnard MD

@geoff_oxnard

5 years

What is the best biomarker for MET-driven EGFR resistance? Elegant work from @danieltanmd suggesting we shouldn't use MET polysomy (i.e. CNG>=5) as a marker of resistance!

1

13

37

Geoff Oxnard MD

@geoff_oxnard

4 years

Exciting new data from @yonsei_u & @JanssenUS in @CD_AACR re "amivantamab" in #EGFR exon20ins. The EGFR/MET mAb induces greater response than poziotinib or cetuximab in vivo. 2 dramatic pt responses shown too! More data soon at #ASCO20 :

2

17

36

Geoff Oxnard MD

@geoff_oxnard

2 years

Action packed introduction to ctDNA - "dawn of a new era" by @BrunaPellini at @ASCO this AM. Bravo Bruna!

0

5

36

Geoff Oxnard MD

@geoff_oxnard

5 years

Tricky to manage brain mets, here’s some added complexity from my colleagues ⁦⁦ @DanaFarber ⁩: Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases. | JAMA Oncology

2

8

36

Geoff Oxnard MD

@geoff_oxnard

2 years

Fascinating and consistent w my clinical experience. Several NSCLC drivers are IO resistant, not clear MET is one of them. Would love to see a tolerable MET/IO combo? @DrMarkAwad @alexdrilon @DrRaviSalgia

Clinical Lung Cancer

@ClinicalLung

2 years

Just out @ClinicalLung ! First-line #pembrolizumab in metastatic NSCLC with MET exon 14 skipping mutation and PD-L1 ≥50% (GFPC 01-20 study) The obective response rate was 43% (14% complete response) with duration of response 13.9 months. Learn more:

1

38

100

3

8

37

Geoff Oxnard MD

@geoff_oxnard

1 year

Excited to collaborate this evidence re ctDNA tumor fraction with our colleagues @ChristianRolfo and @HatimHusainMD ! Please come by the poster and check it out...

0

4

36

Geoff Oxnard MD

@geoff_oxnard

2 years

Nice @BrJCancer review of liquid biopsy in prostate cancer, describing detection of HRRm, AR alts, MSI-H, TMPRSS2-ERG fusions, ctDNA fraction, etc:

0

10

34

Geoff Oxnard MD

@geoff_oxnard

5 years

@JFreemanDaily @theNCI Oncologists must remember the changing treatment landscape when asked to estimate a patient's prognosis. Prognosis estimates are based on historical precedent, and these data show that historical precedent is rapidly out of date! Am carrying that optimism with me to #ASCO2019 .

2

13

35

Geoff Oxnard MD

@geoff_oxnard

6 years

Nice report from Foundation Medicine in JTO showing acquired gene fusions are real and potentially targetable in EGFR-mutant NSCLC, confirming our findings in osi resistance:

1

18

32

Geoff Oxnard MD

@geoff_oxnard

3 years

F1LCDx now FDA approved for detection of MET exon 14 skipping mutations as a companion diagnostic for capmatinib! Now with CDx indications for 9 therapies in 4 cancer types. So proud of the @FoundationATCG team.

0

9

33

Geoff Oxnard MD

@geoff_oxnard

11 months

8/10 I’m also AMAZED🤯by the #ASCO23 LIBELULE study, a randomized trial demonstrating that early liquid biopsy for radiologic suspicion of stage IV lung cancer reduces time to initiation of 1st-line therapy:

LIBELULE: A randomized phase III study to evaluate the clinical relevance of early liquid biopsy...

9019 Background: Timeliness of molecular testing is essential to minimize the time to appropriate 1st line treatment initiation (TTI) in advanced NSCLC pts. We hypothesized that LB-based molecular...

ascopubs.org

3

13

33

Geoff Oxnard MD

@geoff_oxnard

2 years

Gorgeous day for a visit to the growing @FoundationATCG site in La Jolla. It's been 20 years since I was here last - it's become a truly remarkable health sciences hub.

0

30

Geoff Oxnard MD

@geoff_oxnard

4 years

A thought provoking look back and forward by ⁦Dr. Julia Rotow.⁩ Who could have predicted that our most compelling drug combos today would be with chemo! What’s Old Is New Again: Revisiting Up-Front Chemotherapy in EGFR-Mutated NSCLC

What’s Old Is New Again: Revisiting Up-Front Chemotherapy in EGFR-Mutated Non–Small-Cell Lung Cancer

ascopubs.org

1

10

31

Geoff Oxnard MD

@geoff_oxnard

3 years

Thank you Takayuki Yoshino for presenting #ASCO2021 on bTMB experience from 9312 F1LCDx cases. With elevated tumor fraction (TF) the concordance with tissue TMB is clear. Key to understand the TF of our liquid biopsies for maximal learnings!

0

9

32

Geoff Oxnard MD

@geoff_oxnard

6 years

I love discovering a new flavor of statistical bias. Here is a nice article studying ‘optimism bias’, which impairs us from designing adequately powered clinical trials:

3

13

31

Geoff Oxnard MD

@geoff_oxnard

1 year

Craziest part of this monitoring study may be the extensive CH filtering: ⏩ctDNA panel avoided 'CHIP genes' ⏩still, paired PBMC filtered plasma variants in 64% pts, switching ~10% pts from ctDNA+ to neg. 🤯Any ctDNA monitoring assay needs a plan to address CH contamination!

Geoff Oxnard MD

@geoff_oxnard

1 year

Super exciting to work with @genentech on this creative analysis in @NatureMedicine of IMpower150 demonstrating the power of ctDNA monitoring to predict outcome on chemoIO:

3

44

136

0

13

30

Geoff Oxnard MD

@geoff_oxnard

2 years

Super excited to attend @isliquidbiopsy 2022 in Miami next week & present some 🔥 new research w liquid biopsy thought leaders like @ChristianRolfo and @pashtoonkasi ! Hope to see you all there...

International Society of Liquid Biopsy

@isliquidbiopsy

2 years

Meet Christian Rolfo at #ISLB2022 ! Christian is Professor of Medicine (Hematology and Medical Oncology) and Associate Director for Clinical Research in the Center for Thoracic Oncology at The Tisch Cancer Institute. Register today: @ChristianRolfo

0

9

19

1

3

32

Geoff Oxnard MD

@geoff_oxnard

1 year

Such a privilege to be invited to Kokilaben Dhirubhai Ambani, Mumbai to speak on liquid biopsy and the future of precision oncology! @isliquidbiopsy @The_BMC

Anu R I

@anu_iris

1 year

Keynote: Evolution of Precision Oncology (Liquid Biopsy) 🔥 Always motivating to hear @geoff_oxnard ! @HarvardAlumni @ASCO #precisiononcology #liquidbiopsy #CancerResearch #oncotwitter #Cancer Intl Symposium on Precision Oncology, Mumbai.

0

3

11

0

4

32

Geoff Oxnard MD

@geoff_oxnard

1 year

Pull up a chair and watch the @pashtoonkasi masterclass on LBx! Happening now at the GI #ASCO23 posters:

3

32

Geoff Oxnard MD

@geoff_oxnard

3 years

What a pleasure for @FoundationATCG to be able to contribute to this @DanaFarber @Mirati & friends @NEJM study. Check out the striking poly-clonality of #G12C resistance detected in ctDNA! Thanks @DrMarkAwad @oncoOuLungCA & colleagues for including our data.

Mark Awad

@DrMarkAwad

3 years

A number of activating KRAS mutations were also detected, both in cis with G12C (G12C --> G12W) and in trans with G12C (G12D/R/V/W, G13D, Q61H, likely due to mutation of the wild-type KRAS allele). Two cases showed high-level focal amplification of the KRAS G12C allele.

2

1

10

0

6

30

Geoff Oxnard MD

@geoff_oxnard

5 years

She Had Stage 4 Lung Cancer, and a Mountain to Climb - The New York Times

0

7

27

Geoff Oxnard MD

@geoff_oxnard

1 year

Agreed! Fusions in RET, ALK, BRAF, FGFR all appear targetable in EGFR resistance @EGFRResisters , are a key component to resistance profiling, and should be detectable with an appropriately designed LBx:

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA

AbstractPurpose:. Oncogenic kinase fusions are targetable with approved and investigational therapies and can also mediate acquired resistance (AR) to targeted therapy. We aimed to understand the...

aacrjournals.org

Gʀᴇɢᴏʀʏ Rɪᴇʟʏ

@RielyMD

1 year

More data to support paradigm of identifying additional drivers in NSCLC at time of resistance to first targeted therapy. In rare patients with EGFRm NSCLC that acquire RET fusions, osimertinib + selpercatinib leads to 50% resp rate. from @alexdrilon @MSK_DeptOfMed in @CCR_AACR

4

15

60

1

12

30

Geoff Oxnard MD

@geoff_oxnard

5 years

Congrats to ⁦ @skopetz ⁩ et al on successfully tackling BRAF V600E CRC. TKI/mab synergy has been elusive, but here it is! (Can someone mention to ⁦ @NEJM ⁩ it’s a MEK not MET inhibitor?)

0

13

28

Geoff Oxnard MD

@geoff_oxnard

3 years

My team @FoundationATCG is looking for an experienced investigator passionate about NGS to serve as ▶️Global Medical Lead◀️ for our CGP Franchise (both🔬 & 🩸). Bring your 🔥💡🧠🔨& come help us to change precision cancer care! Please DM or .

Global Medical Lead

About the Job Two key FMI products, FoundationOne® CDx (F1CDx) and FoundationOne Liquid CDx (F1LCDx), along with complementary RNA and IHC-based assays, fit together into a CGP franchise designed to...

hcyc.fa.us2.oraclecloud.com

0

4

28

Geoff Oxnard MD

@geoff_oxnard

2 years

Super excited for our new data @myESMO : ⏩New HRDsig could select pancreatic cancer pts for FOLFIRINOX, w @PancPathologist ⏩SPOP muts could select HSPC pts for anti-androgen over chemo, w @neerajaiims ⏩RICTOR amp enriched in NSCLC brain mets, w @DrSteveMartin ⏩And more...

Foundation Medicine

@FoundationATCG

2 years

Excited to join oncology leaders and researchers at #ESMO2022 and feature new research, including data that reinforces the value of Foundation Medicine’s emerging novel homologous recombination deficiency signature. More about the data being presented:

0

4

9

2

11

28

Geoff Oxnard MD

@geoff_oxnard

1 year

More🧬ctDNA monitoring on IO! But using paired PBMC to filter CHIP, like our recent @NatureMedicine paper, so hard to scale clinically: Could a tumor-informed approach offer a cleaner signal & greater sensitivity? Tune in at #ASCO23 for 🔥 new data!

A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small...

Nature Medicine - A machine learning model that uses longitudinal ctDNA metrics robustly predicts survival in two phase 3 trials of patients with metastatic NSCLC, which may improve therapy...

www.nature.com

JCO Precision Oncology

@JCOPO_ASCO

1 year

ctDNA kinetics during the first 3 weeks of immunotherapy can predict treatment outcomes in early phase clinical trials ➡️

0

5

13

1

8

27

Geoff Oxnard MD

@geoff_oxnard

2 years

How about that - work from @DrMarkAwad shows higher recurrence risk with elevated TMB and PDL1 IHC in resected NSCLC. Anyone else sense a therapeutic opportunity?!

Dana-Farber News

@DanaFarberNews

2 years

At #AACR22 João Alessi, MD ( @alessi_joao ), presents on genomic and immunologic factors associated with recurrence after surgery in stage I #NSCLC . Abstract 👉

4

13

52

0

2

25

Geoff Oxnard MD

@geoff_oxnard

2 years

I am an oncologist because of Dr. Vogelzang, my first mentor in med school @UChiPritzker . Thank you Nick for helping to send me (and so many others) on this rewarding path. May your memory be eternal.

Brett Clarkson

@BrettClarkson_

2 years

He was a world-renowned cancer doctor who gave his cellphone number to his patients. Las Vegas oncologist Nicholas Vogelzang dies at 72:

2

3

18

1

25

Geoff Oxnard MD

@geoff_oxnard

2 years

A privilege to collaborate with Arnaud Bayle and @GustaveRoussy to study the utility of liquid biopsy for detecting actionable alterations and enabling trial enrollment across cancer types:

0

26

Geoff Oxnard MD

@geoff_oxnard

4 years

@tmprowell At a minimum I can say that, zoom or no-zoom, neck ties are OUT. Those things have been collecting pathogens for years. No, I'm going full @TonyMok9 ! Who else is with me? #LCSM

2

25

Geoff Oxnard MD

@geoff_oxnard

11 months

Love the ctDNA response waterfall plots! Great to see drugs targeting EGFR C797S progressing. 👇 Congrats @YYElamin and colleagues! 👏

Dr. Antonio Calles 🫁🚭

@Tony_Calles

1 year

BLU-945, 4th generation EGFR TKI, in monotherapy and in combination with osimertinib in previously treated patients with advanced EGFR-mutant NSCLC (phase 1/2 SYMPHONY study) #ASCO23 #LCSM

1

11

31

0

7

24

Geoff Oxnard MD

@geoff_oxnard

1 year

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-ba...

npj Precision Oncology - Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling

www.nature.com

0

6

25

Geoff Oxnard MD

@geoff_oxnard

2 years

Appreciate forward thinking from @myESMO ! Including need for LBx (in a hard to bx dz) covering IDH1, HER2, BRAF, FGFR2 fusions, NTRK fusions, MSI, Lynch genes. Would appreciate some guideline alignment w @NCCN given exploding tx landscape! @pashtoonkasi @VivekSubbiah @jberchuck

Arndt Vogel

@ArndtVogel

2 years

🔥Biliary tract cancer: EMSO Clinical practice guideline for diagnosis, treatment and follow-up🔥 @Annals_Oncology 👉We provide update &💪 recommendations for adjuvant 💊, NGS &🎯 therapies 🙏 to all authors & ESMO team @EASLedu @myESMO #LiverTwitter

0

76

164

1

6

24

Geoff Oxnard MD

@geoff_oxnard

4 years

With two FDA approved CGP tests, we’re now able to help more patients benefit from precision #cancer care. @PritiHegde and I shared our thoughts on this important milestone in a recent blog:

0

6

24

Geoff Oxnard MD

@geoff_oxnard

3 years

HER3/ERBB3 is such an interesting emerging oncogene! This same co-existence with HER2 is seen in NSCLC () and CRC (). Presumably can either occur de novo or through acquired resistance?

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in...

Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.

acsjournals.onlinelibrary.wiley.com

Paolo Tarantino

@PTarantinoMD

3 years

Good read just out on @NEJM , highlighting the clinical implications of the @Cancer_Cell paper by Hanker et al. on HER3 mutations within HER2-mutant BC #bcsm

1

6

29

1

2

22

Geoff Oxnard MD

@geoff_oxnard

2 years

Wow. 👉 More evidence FGFR2 is a pan-tumor biomarker AND 👉 More FGFR2 drugs available AND 👉 New data coming this week @isliquidbiopsy 2023 w @pashtoonkasi showing detection of FGFR2 rearr across cancer types in ctDNA! Sounds like a recipe for patient impact?...

Arndt Vogel

@ArndtVogel

2 years

🔥FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: Is there hope? 🔥 ✅4 intersting cases responding to FGFRi 👉all KRAS WT with comparable long survival 🧐non-typical fusion partners 🎯Early NGS in KRAS WT #PDAC ❗️ @myESMO @OncoAlert

2

27

77

0

3

23

Geoff Oxnard MD

@geoff_oxnard

2 years

Great podcast by #LCSM master @JackWestMD discussing with @DrMarkAwad @DanaFarber his new @JAMAOnc paper! They propose "very high TMB" can be used to "tip the scales" towards IO alone in some pts with advanced NSCLC:

High TMB in NSCLC and Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade

Interview with Mark M. Awad, MD, PhD, author of 'Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1...

edhub.ama-assn.org

0

9

23

Geoff Oxnard MD

@geoff_oxnard

2 years

Wow, fantastic. Anyone else wish they had THIS guy as a boss for a few formative years? 'lets get this guy in front of a crowd'! @sloan_kettering @MSK_DeptOfMed @ASCO @CliffordHudis

Mark Robson

@MarkRobsonMD

2 years

'Tis the season for annual performance reviews. Sharing some reflections on definitions of success in academic medicine. As always, thanks for reading. Be well, stay safe. On Impact, by @MarkRobsonMD

20

53

243

2

1

20

Geoff Oxnard MD

@geoff_oxnard

4 years

Seems like these cfDNA MRD approaches keep getting cooler! This from @hthrparsons @DanaFarber and Blood Biopsy Team @broadinstitute . In resected breast cancer, first WES then a bespoke assay tracking up to 346 variants:

0

4

22

Geoff Oxnard MD

@geoff_oxnard

10 months

More evidence highlighting the value of CGP🧬 to guide first-line NSCLC care! Fortunate to have been involved in the development of this therapy💊, which dramatically impacted my many RET+ pts back at @DanaFarber . 👉 @RetRenegades @LoxoLillyOnc

Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progressio...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based...

www.prnewswire.com

1

4

22

Geoff Oxnard MD

@geoff_oxnard

9 months

Super proud of the @FoundationATCG team, in collab with Nadine Tung & @BIDMChealth , reporting in @Nature_NPJ on potential germline variants on our clinical CGP. Huge opportunity to help pts through referral to germline testing:

Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling comple...

npj Precision Oncology - Potential pathogenic germline variant reporting from tumor comprehensive genomic profiling complements classic approaches to germline testing

www.nature.com

1

10

22

Geoff Oxnard MD

@geoff_oxnard

5 years

@drnirmalraut @OncJournal @LeciaSequist @JackWestMD @CharuAggarwalMD @PatelOncology @VanitaNoronha @Alfdoc2 Are we sure these PIK3CA/BRCA/NOTCH mutations should be considered TKI-resistant? De novo TKI resistance in EGFR-mutant NSCLC can certainly occur, but preclinical studies (&clinical experience) suggests it is thankfully the exception, not the rule.

1

7

21

Geoff Oxnard MD

@geoff_oxnard

3 years

POLE and POLD1 are already on the F1LCDx ctDNA platform, two of >300 genes reported! Somatic and germline both detected. Label with more details at . @FoundationATCG

Jason Starr

@drjasonstarr

3 years

@pashtoonkasi @TumorBoardTues @BHuffmanMD ctDNA platforms need to add POLE and POLD to their panels

0

4

6

3

6

22

Geoff Oxnard MD

@geoff_oxnard

3 years

Looking forward to @ASCO #GU21 presentation today by my @FoundationATCG colleague Hanna Tukachinsky! Prostate cancer ctDNA rich with signal, including BRCA1/2, complex AR resistance mechanisms, etc. More details in our concurrent @CCR_AACR paper:

0

4

22

Geoff Oxnard MD

@geoff_oxnard

1 year

Great TMB review! One added paper to consider, just out in @jitcancer w @DavidRSpigel @DCarboneMD @sands_jacob : 👉Our RWE suggests aNSCLC w TMB>20 may be candidates for a chemo-sparing IO alone approach (even when PDL1<50)...

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint...

Background For patients with advanced non-small cell lung carcinoma (NSCLC), immune checkpoint inhibitor (ICPI) and chemotherapy (chemo) ICPI represent two distinct first-line standard-of-care...

jitc.bmj.com

Yakup Ergün

@dr_yakupergun

1 year

Clinical and technical insights of tumour mutational burden in NSCLC 🔹At least how many genes should be evaluated? 🔹What should be the cut-off for TMB? 🔹Can TMB be evaluated with liquid biopsy? An excellent review👇 @ChristianRolfo @OncoAlert

2

30

67

2

3

21

Geoff Oxnard MD

@geoff_oxnard

1 year

And here's the newest data from David Gandara at #ASCO23 across >8000 pts! Using the FDA approved TMB biomarker, consistent prognostic effect across cancer types:

Timothy Chan

@GeneCollector

1 year

@marklewismd @NEJM @MSKCancerCenter Heh not gonna get triggered this time Mark😂😂. But I will just mention that this paper is underpowered and uninterpretable. One example… many others show in head and neck SCC tmb is predictive. Example below.

3

2

4

1

4

22

Geoff Oxnard MD

@geoff_oxnard

1 year

Now that's an #ASCO23 breakfast! Ready for the @ASCO awards session and a full day of cancer science.

1

0

20

Geoff Oxnard MD

@geoff_oxnard

11 months

Excellent commentary by @harpreet_md @FDAOncology on a complex drug development challenge that has bedeviled me for years! 👏 💡Am hopeful that ctDNA 🩸🧬 monitoring could help to solve the contribution of components challenge with less risk to pts?🤞

Continuation of Third-Generation Tyrosine Kinase Inhibitors in Second-Line Trials for EGFR-Mutated...

ascopubs.org

2

20

Geoff Oxnard MD

@geoff_oxnard

2 years

Stakeholders Urge Collaboration to Prove ctDNA as Regulatory Endpoint for Early Cancer Drugs

Hoping to avoid past pitfalls, industry, research, and clinical sectors pledge to work together to expedite circulating tumor DNA as an early endpoint in clinical trials.

www.genomeweb.com

1

2

19

Geoff Oxnard MD

@geoff_oxnard

3 years

We treated a number of pts with germline T790M in our cohort @DanaFarber and they have no excess toxicity, and in fact can have quite durable benefit! Osimertinib inhibits driver EGFRm +/- T790M, but not clear it inhibits just T790M (which likely is not a driver on its own).

Santhosh Ambika

@RenoHemonc

3 years

@Jbauml @drandrewrob @StephenVLiu @VamsiVelcheti @CarolineMccoach @DrJaredWeiss @kamarrone @benlevylungdoc @xako22 @christine_lovly @rdoebele @WadeIams @HornLeora @patilmd3 @geoff_oxnard Amazing collab! Side q-Have you seen any pts with germline T790m on Osi? , does Osi cause more toxicity in those?

1

0

3

0

4

21

Geoff Oxnard MD

@geoff_oxnard

4 years

Are you age 50 or older and receive care within Partners Healthcare? PATHFINDER study @DanaFarber is still looking for men and women to help evaluate a blood test to detect cancer early. For more information, email pathfinderstudy @dfci .harvard.edu.

Dana-Farber News

@DanaFarberNews

4 years

Results published today in @Annals_Oncology show a new blood test can detect a wide range of #cancers . The test is now available to at risk individuals in clinical study at Dana-Farber:

2

72

112

0

8

19

Geoff Oxnard MD

@geoff_oxnard

5 years

@Tony_Calles @myESMO @OncoAlert And if you believe in lung cancer screening, please also check out our GRAIL data Saturday morning 9:30!

1

3

20

Geoff Oxnard MD

@geoff_oxnard

1 year

Listening to @JackWestMD it becomes clear that, in another life, he could have been a Bob Hope / Howard Cosell radio personality... but I'm glad he's OUR #LCSM @Twitter personality instead! Insightful commentary on this @ASCO podcast with @VamsiVelcheti :

Google Podcasts

With Google Podcasts, you can find and listen to the world's podcasts for free.

podcasts.google.com

1

21

Geoff Oxnard MD

@geoff_oxnard

2 years

Awesome podcast on HRD in pancreatic cancer from @DrNeilLove ! Great work @MPishvaian (with a shout out to @KReissMD ):

Google Podcasts

With Google Podcasts, you can find and listen to the world's podcasts for free.

podcasts.google.com

1

3

20

Geoff Oxnard MD

@geoff_oxnard

5 years

Come see our ⁦ @GrailBio ⁩ poster 39 #ASCO2019 ! Blood based cancer detection may not find ‘good prognosis’ over-diagnosis cancers. Finds morbid cancers that need treatment!

0

5

20

Geoff Oxnard MD

@geoff_oxnard

2 years

@AzadOncology @neerajaiims @ASCO Looks like PROpel determined HRRm by ctDNA, which is great for finding positives BUT negatives should be confirmed on tissue, esp given lower shed in 1L mCRPC. Perhaps MAGNITUDE used tumor for HRRm, thus a more reliable negative result predicting lack of benefit? @EAntonarakis

2

6

20

Geoff Oxnard MD

@geoff_oxnard

1 year

Have to share a fascinating case from a @The_BMC colleague: ▶️Youngish never-smoker p/w advanced lung cancer, mets to bone. ▶️LBx sent while path review pending, see below. Anyone want to take a guess at the diagnosis? And what tx you'd start with?

11

1

19

Geoff Oxnard MD

@geoff_oxnard

2 years

The prognostic significance of ctDNA shed has such potential for influencing cancer care! One potential use we will present @ASCO with @BenjaminBesseMD - ctDNA shed for risk stratification in advanced NSCLC:

Andres F. Cardona

@AndresFCardonaZ

2 years

TNMB system?

23

160

663

1

2

20

Geoff Oxnard MD

@geoff_oxnard

6 years

$LOXO-292 with dramatic plasma responses seen across a full range of doses in RET positive cancers. Very potent drug. #ASCO18

0

10

20

Geoff Oxnard MD

@geoff_oxnard

1 year

Thanks for these tangible action steps by @rschilsky @NEJM ! Many are in flight - guideline updates, EMR linkage, etc. Accessibility of comprehensive LBx will be a key piece of enabling adoption. @isliquidbiopsy Closing the Gap in Cancer Genomic Testing:

Closing the Gap in Cancer Genomic Testing | NEJM

Genomic analysis of tumor tissue and circulating tumor DNA is an increasingly important component of cancer care. But evidence indicates underutilization of tumor genomic testing.

www.nejm.org

0

4

20

Geoff Oxnard MD

@geoff_oxnard

1 year

Congrats to @MGHBreastOnc on this paper showing how a panel of resistance alterations complement ESR1 to inform outcomes to CDK4/6i in MBC! Like T790M in NSCLC, ESR1 is going to just be the tip of the resistance iceberg...

0

5

20

Geoff Oxnard MD

@geoff_oxnard

2 years

Proud of this study of LBx NGS in NSCLC @JTOonline ! Clear value of LBx to detect NCCN biomarkers if added to limited tissue testing. No additional NCCN biomarkers when adding LBx to tissue CGP! With negative LBx, tissue can detect missed NCCN biomarkers:

Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of...

Whereas tumor biopsy is the reference standard for genomic profiling of advanced NSCLC, there are now multiple assays approved by the Food and Drug Administration for liquid biopsy testing of...

www.jtocrr.org

0

9

20

Geoff Oxnard MD

@geoff_oxnard

4 years

Here a fascinating reminder from @RebeccaDRobbins that our plasma cell free DNA is a rich mixture from many sources - germline, tumor, white blood cell, and even microbial:

0

5

19

Geoff Oxnard MD

@geoff_oxnard

1 year

Excited to talk more about the new ctDNA tumor fraction biomarker at @ASCO #ASCO23 :

[Video] Foundation Medicine on LinkedIn: Hear more about tumor...

The level of circulating tumor DNA (ctDNA) shed by a patient’s specific tumor informs the accuracy of blood-based CGP test results. At Foundation Medicine, our…

www.linkedin.com

0

3

20

Geoff Oxnard MD

@geoff_oxnard

8 months

@n8pennell I would bet that brain mets are merely one potential surrogate for tumor burden. I would be interested in seeing this broken down by other measures of aggressiveness like liver mets, TP53 mutation or ctDNA tumor fraction.

1

5

20

Geoff Oxnard MD

@geoff_oxnard

1 year

New in @JTOonline w @n8pennell ! 👉9% of NSCLC CGP results ordered in the early disease setting. 👉CGP prior to recurrence had a shorter time to initiation of therapy. 👉Could CGP also inform adjuvant IO use?

Quantifying the Value of Multigene Testing in Resected Early Stage Lung Adenocarcinoma

Tyrosine kinase inhibitors and immune checkpoint inhibitors (ICIs), each requiring testing for precision biomarkers, have recently been approved in the adjuvant setting. We assessed the potential...

www.jto.org

0

6

18

Geoff Oxnard MD

@geoff_oxnard

11 months

The first liquid biopsy CDx specifically for CRC! Punctuating evidence of the utility of LBx in GI cancers ⏩ increasing the accessibility of CGP testing. @skopetz @pashtoonkasi @aparna1024 @isliquidbiopsy

Foundation Medicine

@FoundationATCG

11 months

#Announcement – FDA approves FoundationOne®Liquid CDx* as a companion diagnostic to identify patients w/ BRAF V600E alterations in mCRC: *Rx only; doesn't guarantee treatment match or that all alterations will be found

0

4

9

0

4

16